Log in

OTCMKTS:LOACULongevity Acquisition Corporation Units Stock Price, Forecast & News

0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
Today's Range
Now: $10.60
50-Day Range
MA: $10.49
52-Week Range
Now: $10.60
Average Volume800 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Longevity Acquisition Corporation does not have significant operations. The company focuses on acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing of assets, entering into contractual arrangements, or other business combination with one or more businesses. Longevity Acquisition Corporation was founded in 2018 and is based in Shanghai, the People's Republic of China.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.56 out of 5 stars

Industry, Sector and Symbol

Industry Conglomerates
Phone86 21 6083 2028



Sales & Book Value

Annual SalesN/A



Next Earnings Date10/14/2020 (Estimated)
OptionableNot Optionable
0.00 (0.00 %)
(As of 08/7/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive LOACU News and Ratings via Email

Sign-up to receive the latest news and ratings for LOACU and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Longevity Acquisition Corporation Units (OTCMKTS:LOACU) Frequently Asked Questions

How has Longevity Acquisition Corporation Units' stock been impacted by COVID-19 (Coronavirus)?

Longevity Acquisition Corporation Units' stock was trading at $10.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, LOACU shares have decreased by 1.0% and is now trading at $10.5955.
View which stocks have been most impacted by Coronavirus

When is Longevity Acquisition Corporation Units' next earnings date?

Longevity Acquisition Corporation Units is scheduled to release its next quarterly earnings announcement on Wednesday, October 14th 2020.
View our earnings forecast for Longevity Acquisition Corporation Units

Has Longevity Acquisition Corporation Units been receiving favorable news coverage?

Media headlines about LOACU stock have trended very negative this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Longevity Acquisition Corporation Units earned a media sentiment score of -3.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future.
View the latest news about Longevity Acquisition Corporation Units

Who are some of Longevity Acquisition Corporation Units' key competitors?

Who are Longevity Acquisition Corporation Units' key executives?

Longevity Acquisition Corporation Units' management team includes the following people:
  • Mr. Matthew Chen, Chairman & CEO (Age 48)
  • Mr. Teddy Zheng, Chief Financial Officer (Age 37)

What is Longevity Acquisition Corporation Units' stock symbol?

Longevity Acquisition Corporation Units trades on the OTCMKTS under the ticker symbol "LOACU."

How do I buy shares of Longevity Acquisition Corporation Units?

Shares of LOACU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Longevity Acquisition Corporation Units' stock price today?

One share of LOACU stock can currently be purchased for approximately $10.60.

How can I contact Longevity Acquisition Corporation Units?

The company can be reached via phone at 86 21 6083 2028.

This page was last updated on 8/9/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.